PCM
GTBP icon

Parsons Capital Management’s GT Biopharma GTBP Stock Holding History

Parsons Capital Management’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.34K Hold
436
– – ﹤0.01% 523
2026
Q1 		$4.45K Hold
436
– – ﹤0.01% 487
2025
Q4 		$8.56K Buy
+436
New +$7.74K ﹤0.01% 461

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
OWA
Opal Wealth Advisors Jericho, New York $463M AUM 20.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM

Parsons Capital Management's GTBP Position: Q2 2026 in Review

Parsons Capital Management held its GT Biopharma (GTBP) position steady in Q2 2026 at 436 shares worth $5.34K. The position accounts for ﹤0.01% of the portfolio, ranked #523.

Parsons Capital Management first reported a position in GTBP in Q4 2025 and has held it in 3 quarters since. The position peaked at $8.56K in Q4 2025. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

  • Parsons Capital Management held 436 shares of GT Biopharma worth $5.34K as of Q2 2026.
  • Parsons Capital Management left its GT Biopharma share count unchanged in Q2 2026.
  • GT Biopharma made up ﹤0.01% of Parsons Capital Management's portfolio in Q2 2026, its #523 holding.
  • Parsons Capital Management first reported a position in GT Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Parsons Capital Management's GT Biopharma position peaked at $8.56K in Q4 2025.
  • 55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Parsons Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.